January 2022 Report

January 2022 Report

New and First Time Generic Drug Report

Download Report

New Brand Drug Pipeline

Medication (Brand name) Drug Class Therapeutic Use Status Update

Baclofen Granules (Lyvispah™)

Muscle Relaxant Muscle Spasms Launch pending. Approved November 22, 2021.
Celecoxib/Tramadol (Seglentis®) NSAID/Opioid Agonist Pain Launch anticipated in 2022. Approved October 19, 2021.
Naloxone Injection (Zimhi™) Opioid Antagonist Opioid Overdose Launch anticipated in 2022. Approved October 18, 2021.
Celecoxib Oral Liquid (Elyxyb™) NSAID Migraine Headache Treatment Launch pending. Approved May 5, 2020.
Buprenorphine Depot
Injection
(Brixadi™)
Opioid Agonist Treatment of
Opioid Addiction
FDA review pending.
Oxycodone (Aximris XR™) Opioid Analgesic –
Extended Release
Pain FDA review pending.
Ansofaxine Antidepressant Major Depressive
Disorder
FDA review pending.
Nalmefene Injection Opioid Antagonist Opioid Overdose FDA review pending.

Generic Pipeline

Medication (Brand name) Drug Class Therapeutic Use Status Update
Dabigatran (Pradaxa®) Anticoagulant Treatment/Prophylaxis of Deep Vein Thrombosis First patent set to expire December 2021. Generic anticipated June 2022.
Oxycodone HCl (Oxaydo®) Opioid Agonist Pain Generic exclusivity anticipated in 2022.
Apixaban (Eliquis®) Anticoagulant Treatment/Prophylaxis of Deep Vein Thrombosis Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years.
Diclofenac Potassium (Zipsor®) Capsule NSAID Pain Patent set to expire March 2022.

Available in the Last 12 Months

Medication (Brand name) Drug Class Therapeutic Use Status Update
Naloxone Nasal Spray (Kloxxado™) Opioid Antagonist Opioid Overdose August 2021

Newly Available Generics

Medication (Brand name) Drug Class Therapeutic Use Status Update
Naloxone HCl (Narcan®) Nasal Spray Opioid Antagonist Opioid Overdose December 2021
Zolmitriptan Nasal Spray (Zomig®) Serotonin Agonist Migraine Headache Treatment November 2021
Nebivolol (Bystolic®) Beta Blocker Beta Blocker September 2021
Ibuprofen/Famotidine (Duexis®) NSAID/H-2 Receptor Antagonist Pain/Inflammation August 2021
Pregabalin Extended Release (Lyrica® CR) Anticonvulsant Neuropathic Pain April 2021
Hydrocodone Bitartrate (Hysingla™ ER) Opioid Agonist – Extended Release Pain March 2021
Topiramate ER Capsule (Qudexy® XR) Anticonvulsant Headache, Neuropathic Pain February 2021

Discontinuations & Withdrawals

Medication (Brand name) Drug Class Therapeutic Use Status Update
Naloxone HCl (Evzio®) Opioid Antagonist Opioid Overdose The manufacturer made a business decision to discontinue in September 2020.

Download Report